See more : EKI Energy Services Limited (EKI.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Bristol-Myers Squibb Company (BMY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bristol-Myers Squibb Company, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
You may be interested
- Tantech Holdings Ltd (TANH) Income Statement Analysis – Financial Results
- SBC Medical Group Holdings Incorporated (SBC) Income Statement Analysis – Financial Results
- ASM International NV (ASMIY) Income Statement Analysis – Financial Results
- Wesdome Gold Mines Ltd. (0VOA.L) Income Statement Analysis – Financial Results
- Wealth Minerals Ltd. (WML.V) Income Statement Analysis – Financial Results
Bristol-Myers Squibb Company (BMY)
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 45.01B | 46.16B | 46.39B | 42.52B | 26.15B | 22.56B | 20.78B | 19.43B | 16.56B | 15.88B | 16.39B | 17.62B | 21.24B | 19.48B | 18.81B | 20.60B | 19.35B | 17.91B | 19.21B | 19.38B | 20.89B | 18.12B | 19.42B | 18.22B | 20.22B | 18.28B | 16.70B | 15.07B | 13.77B | 11.98B | 11.41B | 11.16B | 11.16B | 10.30B | 9.19B | 8.56B | 7.56B |
| Cost of Revenue | 10.69B | 10.14B | 9.94B | 11.77B | 8.08B | 6.55B | 6.07B | 4.95B | 3.91B | 3.93B | 4.62B | 4.61B | 5.60B | 5.28B | 5.14B | 6.40B | 6.22B | 5.96B | 5.93B | 5.99B | 7.59B | 6.39B | 5.58B | 4.01B | 4.86B | 4.23B | 3.87B | 3.45B | 3.19B | 2.79B | 2.72B | 2.56B | 2.68B | 2.63B | 2.46B | 2.30B | 2.14B |
| Gross Profit | 34.31B | 36.02B | 36.45B | 30.75B | 18.07B | 16.01B | 14.71B | 14.48B | 12.65B | 11.95B | 11.77B | 13.01B | 15.65B | 14.21B | 13.67B | 14.20B | 13.13B | 11.96B | 13.28B | 13.39B | 13.30B | 11.73B | 13.85B | 14.20B | 15.36B | 14.05B | 12.83B | 11.62B | 10.58B | 9.19B | 8.69B | 8.59B | 8.48B | 7.67B | 6.73B | 6.26B | 5.42B |
| Gross Profit Ratio | 76.24% | 78.04% | 78.57% | 72.31% | 69.10% | 70.98% | 70.80% | 74.54% | 76.39% | 75.24% | 71.81% | 73.84% | 73.65% | 72.92% | 72.67% | 68.95% | 67.86% | 66.75% | 69.14% | 69.10% | 63.66% | 64.74% | 71.30% | 77.97% | 75.96% | 76.86% | 76.81% | 77.13% | 76.84% | 76.69% | 76.16% | 77.03% | 75.95% | 74.47% | 73.23% | 73.14% | 71.67% |
| Research & Development | 9.30B | 9.51B | 10.20B | 11.14B | 6.15B | 6.35B | 6.41B | 4.94B | 5.92B | 4.53B | 3.73B | 3.90B | 3.84B | 3.57B | 3.65B | 3.59B | 3.28B | 3.07B | 2.75B | 2.50B | 2.28B | 2.22B | 2.26B | 1.94B | 1.84B | 1.58B | 1.39B | 1.28B | 1.20B | 1.11B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 6.28B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 162.00M | 91.00M | 160.00M | 877.00M | 165.00M | 158.00M | 4.20B | 3.56B | 4.08B | 4.83B | 4.86B | 4.92B | 5.11B | 5.02B | 4.66B | 3.92B | 3.90B | 3.86B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 1.40B | 7.81B | 7.69B | 7.66B | 4.87B | 4.55B | 4.69B | 4.91B | 4.84B | 4.82B | 4.94B | 5.02B | 957.00M | 977.00M | 1.14B | 1.55B | 1.47B | 1.35B | 1.48B | 1.41B | 1.42B | 1.30B | 1.43B | 1.67B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.77B | 7.81B | 7.69B | 7.66B | 4.87B | 4.55B | 4.85B | 5.00B | 5.00B | 5.70B | 5.10B | 5.18B | 5.16B | 4.54B | 5.21B | 6.38B | 6.32B | 6.27B | 6.58B | 6.43B | 6.08B | 5.22B | 5.34B | 5.53B | 6.99B | 6.73B | 6.41B | 5.87B | 5.32B | 4.53B | 5.98B | 6.34B | 5.46B | 5.04B | 5.45B | 4.30B | 3.79B |
| Other Expenses | 0.00 | 9.60B | 10.02B | 9.76B | 1.14B | 1.37B | 1.40B | 1.00B | 621.00M | 313.00M | 133.00M | 245.00M | 0.00 | 284.00M | -931.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 746.00M | 678.00M | 625.00M | 591.00M | 519.00M | 448.00M | 328.00M | 308.00M | 295.00M | 246.00M | 244.00M | 196.00M | 185.00M | 161.00M |
| Operating Expenses | 34.31B | 26.92B | 27.91B | 28.57B | 12.15B | 10.90B | 11.26B | 9.94B | 10.92B | 10.23B | 8.84B | 9.08B | 8.61B | 7.71B | 8.86B | 8.48B | 9.60B | 9.34B | 9.33B | 8.93B | 8.36B | 7.44B | 7.60B | 8.22B | 9.51B | 8.93B | 8.39B | 7.67B | 6.96B | 5.97B | 6.29B | 6.63B | 5.71B | 5.28B | 5.65B | 4.49B | 3.95B |
| Cost & Expenses | 27.76B | 37.06B | 37.85B | 40.34B | 20.23B | 17.44B | 17.33B | 14.89B | 14.83B | 14.17B | 13.45B | 13.69B | 14.21B | 12.98B | 14.00B | 14.88B | 15.82B | 15.29B | 15.26B | 14.92B | 15.95B | 13.82B | 13.17B | 12.23B | 14.37B | 13.16B | 12.26B | 11.11B | 10.15B | 8.76B | 9.01B | 9.20B | 8.39B | 7.91B | 8.11B | 6.79B | 6.09B |
| Interest Income | 0.00 | 171.00M | 120.00M | 121.00M | 464.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 91.00M | 75.00M | 54.00M | 130.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.17B | 1.23B | 1.33B | 1.42B | 656.00M | 183.00M | 196.00M | 167.00M | 184.00M | 203.00M | 199.00M | 182.00M | 145.00M | 145.00M | 184.00M | 310.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 410.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 9.81B | 10.29B | 10.76B | 10.49B | 1.81B | 703.00M | 872.00M | 626.00M | 376.00M | 467.00M | 763.00M | 681.00M | 801.00M | 744.00M | 707.00M | 816.00M | 892.00M | 927.00M | 929.00M | 909.00M | 789.00M | 735.00M | 781.00M | 746.00M | 678.00M | 625.00M | 591.00M | 519.00M | 448.00M | 328.00M | 308.00M | 295.00M | 246.00M | 244.00M | 196.00M | 185.00M | 161.00M |
| EBITDA | 19.37B | 19.23B | 20.19B | 5.04B | 7.44B | 6.85B | 6.20B | 4.63B | 2.94B | 3.41B | 4.40B | 3.51B | 7.93B | 7.09B | 6.61B | 6.60B | 4.42B | 3.31B | 4.67B | 5.37B | 5.72B | 4.84B | 5.89B | 6.73B | 5.92B | 5.08B | 5.03B | 4.47B | 4.06B | 3.55B | 2.71B | 2.26B | 3.01B | 2.63B | 1.28B | 1.96B | 1.63B |
| EBITDA Ratio | 43.03% | 43.16% | 43.51% | 34.85% | 25.24% | 26.91% | 27.52% | 28.91% | 14.70% | 13.44% | 19.71% | 24.74% | 33.54% | 33.75% | 22.92% | 28.99% | 24.59% | 21.12% | 23.16% | 28.31% | 28.37% | 35.29% | 52.78% | 40.01% | 32.61% | 35.73% | 29.78% | 29.40% | 38.63% | 35.64% | 21.78% | 19.53% | 25.41% | 23.70% | 11.12% | 20.60% | 18.72% |
| Operating Income | 17.24B | 10.33B | 10.16B | 5.13B | 5.46B | 5.12B | 3.45B | 4.54B | 1.73B | 1.71B | 2.93B | 3.93B | 6.65B | 5.61B | 5.74B | 4.24B | 3.53B | 2.62B | 3.95B | 4.46B | 4.95B | 4.30B | 6.25B | 5.99B | 5.85B | 5.12B | 4.44B | 3.95B | 3.62B | 3.22B | 2.40B | 1.96B | 2.77B | 2.39B | 1.08B | 1.77B | 1.47B |
| Operating Income Ratio | 38.31% | 22.37% | 21.90% | 12.06% | 20.90% | 22.69% | 16.61% | 23.36% | 10.45% | 10.79% | 17.89% | 22.31% | 31.29% | 28.77% | 30.51% | 20.59% | 18.23% | 14.63% | 20.57% | 23.03% | 23.68% | 23.70% | 32.19% | 32.86% | 28.94% | 28.01% | 26.57% | 26.24% | 26.26% | 26.88% | 21.05% | 17.57% | 24.79% | 23.19% | 11.79% | 20.68% | 19.41% |
| Total Other Income/Expenses | -8.80B | -10.64B | -9.30B | -7.42B | -938.00M | -426.00M | -108.00M | 1.45B | 347.00M | 667.00M | -40.00M | -1.59B | 344.00M | 121.00M | 163.00M | -247.00M | 6.00M | 610.00M | 353.00M | -46.00M | -612.00M | -1.60B | -2.94B | -508.00M | -81.00M | -818.00M | 44.00M | 60.00M | -1.21B | -666.00M | 168.00M | 27.00M | 121.00M | 135.00M | 194.00M | 119.00M | 161.00M |
| Income Before Tax | 8.44B | 7.71B | 8.10B | -6.87B | 4.98B | 6.01B | 5.13B | 5.92B | 2.17B | 2.38B | 2.89B | 2.34B | 6.98B | 6.07B | 5.60B | 5.47B | 3.53B | 2.64B | 4.52B | 4.42B | 4.69B | 2.65B | 2.90B | 5.48B | 5.77B | 4.27B | 4.48B | 4.01B | 2.40B | 2.56B | 2.57B | 1.99B | 2.89B | 2.52B | 1.28B | 1.89B | 1.63B |
| Income Before Tax Ratio | 18.75% | 16.71% | 17.46% | -16.16% | 19.03% | 26.64% | 24.70% | 30.45% | 13.09% | 14.99% | 17.64% | 13.28% | 32.86% | 31.16% | 29.79% | 26.56% | 18.27% | 14.71% | 23.51% | 22.80% | 22.47% | 14.61% | 14.91% | 30.07% | 28.52% | 23.34% | 26.84% | 26.64% | 17.45% | 21.32% | 22.53% | 17.81% | 25.87% | 24.50% | 13.90% | 22.07% | 21.54% |
| Income Tax Expense | 400.00M | 1.37B | 1.08B | 2.12B | 1.52B | 1.03B | 4.16B | 1.41B | 477.00M | 352.00M | 311.00M | -161.00M | 1.72B | 1.56B | 1.18B | 1.32B | 803.00M | 610.00M | 932.00M | 1.52B | 1.22B | 435.00M | 459.00M | 1.38B | 1.60B | 1.13B | 1.28B | 1.16B | 590.00M | 713.00M | 612.00M | 449.00M | 831.00M | 776.00M | 530.00M | 635.00M | 560.00M |
| Net Income | 8.03B | 6.33B | 6.99B | -9.00B | 3.44B | 4.95B | 1.01B | 4.46B | 1.62B | 2.00B | 2.56B | 1.96B | 3.71B | 3.10B | 10.61B | 5.25B | 2.17B | 1.59B | 3.00B | 2.39B | 3.11B | 2.07B | 5.25B | 4.71B | 4.17B | 3.14B | 3.21B | 2.85B | 1.81B | 1.84B | 1.96B | 1.96B | 2.06B | 1.75B | 747.00M | 1.25B | 1.07B |
| Net Income Ratio | 17.83% | 13.71% | 15.08% | -21.16% | 13.15% | 21.95% | 4.85% | 22.94% | 9.81% | 12.62% | 15.64% | 11.12% | 17.46% | 15.92% | 56.42% | 25.47% | 11.19% | 8.85% | 15.62% | 12.32% | 14.87% | 11.40% | 27.00% | 25.86% | 20.61% | 17.18% | 19.19% | 18.92% | 13.16% | 15.37% | 17.16% | 17.59% | 18.42% | 16.97% | 8.13% | 14.65% | 14.13% |
| EPS | 3.88 | 2.97 | 3.15 | -3.98 | 2.02 | 3.03 | 0.61 | 2.67 | 0.97 | 1.21 | 1.56 | 1.17 | 2.18 | 1.81 | 5.38 | 2.65 | 1.10 | 0.81 | 1.54 | 1.23 | 1.60 | 1.03 | 2.70 | 2.40 | 2.10 | 1.58 | 1.61 | 1.42 | 0.90 | 0.90 | 0.95 | 0.96 | 0.99 | 0.84 | 0.36 | 0.60 | 0.50 |
| EPS Diluted | 3.86 | 2.95 | 3.12 | -3.98 | 2.01 | 3.03 | 0.61 | 2.65 | 0.97 | 1.20 | 1.54 | 1.16 | 2.16 | 1.80 | 5.37 | 2.62 | 1.09 | 0.81 | 1.51 | 1.21 | 1.59 | 1.02 | 2.67 | 2.36 | 2.06 | 1.55 | 1.57 | 1.40 | 0.89 | 0.90 | 0.95 | 0.96 | 0.99 | 0.84 | 0.36 | 0.60 | 0.50 |
| Weighted Avg Shares Out | 2.07B | 2.13B | 2.22B | 2.26B | 1.71B | 1.63B | 1.65B | 1.67B | 1.67B | 1.66B | 1.64B | 1.67B | 1.70B | 1.71B | 1.97B | 1.98B | 1.97B | 1.96B | 1.95B | 1.94B | 1.94B | 2.00B | 1.94B | 1.97B | 1.98B | 1.99B | 1.99B | 2.01B | 2.02B | 2.04B | 2.06B | 2.04B | 2.08B | 2.08B | 2.08B | 2.09B | 2.14B |
| Weighted Avg Shares Out (Dil) | 2.08B | 2.15B | 2.25B | 2.26B | 1.71B | 1.64B | 1.65B | 1.68B | 1.68B | 1.67B | 1.66B | 1.69B | 1.72B | 1.73B | 1.98B | 2.00B | 1.98B | 1.96B | 1.98B | 1.98B | 1.95B | 2.02B | 1.97B | 2.00B | 2.03B | 2.03B | 2.04B | 2.04B | 2.03B | 2.04B | 2.06B | 2.04B | 2.08B | 2.08B | 2.08B | 2.09B | 2.14B |
Bristol-Myers Squibb Company (BMY) Citi's 2024 Global Healthcare Conference (Transcript)
Bristol-Myers Squibb Company (NYSE:BMY ) Citi's 2024 Global Healthcare Conference December 3, 2024 8:00 AM ET Company Participants Christopher Boerner - CEO and Board Chair David Elkins - EVP and CFO Conference Call Participants Geoff Meacham - Citi Mary Kate...
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
Is Bristol-Myers Squibb Stock a Millionaire Maker?
Bristol-Myers Squibb (BMY -0.08%) is the kind of stock that potentially has a lot to offer to investors looking for wealth-building investments. With a large repertoire of medicines on the market, and a constant stream of programs approaching maturity and...
3 Magnificent S&P 500 Dividend Stocks Down 27%, 28%, and 29% to Buy and Hold Forever
Finding attractive dividend stocks you can hold isn't too difficult. Finding dividend stocks you can comfortably buy and hold forever is a different story.
Calls of the Day: Martin Marietta, Datadog, Bristol-Myers, Eli Lilly and Disney
The Investment Committee debate the latest Calls of the Day.
BMY Stock vs. JNJ Stock
Given its better prospects, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pharmaceutical pick over Johnson & Johnson stock (NYSE: JNJ). BMY stock trades at 8.3x its forward expected earnings (2025), versus 14.7x for JNJ.
Bristol Myers Squibb to Participate in Citi's 2024 Global Healthcare Conference
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in Citi's 2024 Global Healthcare Conference.
Prime Medicine's Bristol Myers Partnership Boosts Outlook For Gene Editing Therapies
Prime Medicine's proprietary Prime Editing platform offers one-time therapeutic solutions, targeting over 90% of genetic conditions across multiple tissues and development stages. PRME's pipeline highlights PM359 for chronic granulomatous disease and preclinical programs for Wilson's Disease, with clinical data expected...
5 Reasons Bristol-Myers Squibb Looks Good Now (Rating Upgrade)
Bristol-Myers Squibb's price continues to rise due to a confluence of factors, not the least of which is an earnings surprise in Q3 2024. The company's raised guidance for 2024 is also encouraging, as is the FDA's approval for its...
One Sector Has Underperformed Massively: These 4 Blue-Chip Dividend Giants Are Huge 2025 Plays
Key Points Donald Trump's victory is positive for the stock market.
Source: https://incomestatements.info
Category: Stock Reports